This is a low-impact R&D collaboration with no near-term catalyst. Monitor for publication of psoriasis model results later this year and any subsequent clinical data readouts for ART26.12. No immediate trading action warranted given the $4M market cap and lack of financial details.
Price Chart
Executive Summary
Artelo Biosciences announced a strategic partnership with AI company ScienceMachine to accelerate development of its FABP5 inhibitor platform, including lead candidate ART26.12. The collaboration uses AI to analyze biological datasets and has already identified novel protein and lipid signatures correlated with ART26.12's analgesic effect. This is a non-financial R&D collaboration with no disclosed deal value, milestone payments, or revenue impact.
Key Facts
- Partnership with ScienceMachine to use AI for FABP5 inhibitor development, including ART26.12
- AI analysis identified potential proteins indicative of FABP5 target engagement from Phase 1 data
- Preliminary results in a psoriasis model slated for publication later in 2026
- No financial terms, milestone payments, or equity investment disclosed
- Artelo is the first company to bring a selective FABP5 inhibitor into human studies for neuropathic pain
Financial Impact
No financial terms disclosed; partnership is non-dilutive R&D collaboration
Risk Factors
- No disclosed deal value or milestone payments — partnership may not generate near-term value
- Clinical-stage biotech with no approved products; high cash burn risk
- Forward-looking statements about AI acceleration are unproven at this stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282634 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.21 (+28.91%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.21 (−41.04%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.21 (−67.63%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.21 (+93.94%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.21 (+93.94%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.21 (+110.56%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.21 (−99.18%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.21 (−51.43%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.21 (+62.57%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.21 (+51.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers